Subscribe
Photo Nature Travel / Shutterstock.com
14 January 2025NewsBig PharmaLiz Hockley

Novartis wins appeal in MSN clash over heart drug generic

Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSN scores win in battle with Novartis over heart drug generic
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
Novartis fails to block first heart-failure generic by Indian rival
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
MSN scores win in battle with Novartis over heart drug generic
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
Novartis fails to block first heart-failure generic by Indian rival
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More on this story

Americas
MSN scores win in battle with Novartis over heart drug generic
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
Novartis fails to block first heart-failure generic by Indian rival
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More features

Gowling WLG’s legal director jumps to Osborne Clarke
Takeda loses AMR treatment patent used in kidney transplants
Withers & Rogers hires cell and gene therapy expert
Medtech firm strikes out part of Apple button patent in ECG row
Tissue repair VP gets new trial over secrets damages
Labcorp's bid to invalidate Ravgen's DNA testing patent hits roadblock
Troutman Pepper Locke exodus sees teams leave in Chicago and London
Ex-Baker McKenzie patent litigation head joins Morgan Lewis in Germany